Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076184 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Konstantin R Brawanski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinischer Forschungsfond Innsbruck.
Abstract (Originalsprache)
Glioblastoma is the most common malignant brain tumor in adults. Standard treatment includes tumor resection, radio-chemotherapy and adjuvant chemotherapy with temozolomide (TMZ). TMZ methylates DNA, whereas O6-methylguanine DNA methyltransferase (MGMT) counteracts TMZ effects by removing the intended proteasomal degradation signal. Non-functional MGMT mediates the mismatch repair (MMR) system, leading to apoptosis after futile repair attempts. This study investigated the associations between MGMT promoter methylation, MGMT and MMR protein expression, and their effect on overall survival (OS) and progression-free survival (PFS) in patients with glioblastoma. MGMT promoter methylation was assessed in 42 treatment-naïve patients with glioblastoma WHO grade IV by pyrosequencing. MGMT and MMR protein expression was analyzed using immunohistochemistry. MGMT promoter methylation was present in 52%, whereas patients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.
- Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
- Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.
- Diagnostic and Research Center for Molecular Biomedicine, Diagnostic and Research Institute of Pathology, Medical University of Graz, 8036 Graz, Austria.
ORCID-Profile: Christian F Freyschlag, Anna M Birkl-Toeglhofer
Förderung
- Medizinischer Forschungsfond Innsbruck
Zitieren
APA
Brawanski, K. R., Sprung, S., Freyschlag, C. F., Hoeftberger, R., Ströbel, T., Haybaeck, J., Thomé, C., Manzl, C., & Birkl-Toeglhofer, A. M. (2023). Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076184
Vancouver
Brawanski KR, Sprung S, Freyschlag CF, Hoeftberger R, Ströbel T, Haybaeck J, et al. Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076184
BibTeX
@article{Brawanski2023,
author = {Brawanski, Konstantin R and Sprung, Susanne and Freyschlag, Christian F and Hoeftberger, Romana and Ströbel, Thomas and Haybaeck, Johannes and Thomé, Claudius and Manzl, Claudia and Birkl-Toeglhofer, Anna M},
title = {Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076184}
}
EUVIMED